The field of medicine is rushing headlong into a new, information-intensive era of practice and research. As medicine learns to wield the tools of "big data," there is growing confidence that physicians and researchers will be able to obtain, measure, and analyze information from multiple sources-including the directly solicited views and preferences of patients.
In this week's issue of Circulation, Stolker and colleagues provide insight into where this major trend may be headed. 1 Using a simple questionnaire administered to cardiovascular clinic patients, they uncovered several intriguing findings. First, they noted a difference between clinical trialists and patients regarding the importance ascribed by each group to preventing different specific outcomes that comprise the classical major adverse cardiovascular event (MACE) endpoints used to assess the safety and efficacy of cardiovascular therapies. Second, they found that among the patient respondents to their survey, these weightings also varied as a function of demographic factors. On the basis of these findings, Stolker and colleagues propose that weighted composites could be used to personalize evidence assessment to inform healthcare delivery based on these differences.
The measurement of patient preferences has a long history that nevertheless seems to undergo perpetual rediscovery. Yet the key issues in this arena have received scant attention from funding agencies, and very little support has been directed toward research aimed at elucidating patient preferences and decision-making processes. As a result of this inattention, many decisions at the individual, population, and policy levels are made without a true understanding of the preferences of either the downstream decision-makers (doctors, other providers, and administrators) or the patients and caregivers who will be affected. By demonstrating that different people may have notably divergent interpretations regarding the import of clinical trial results, Stolker and colleagues have made a significant contribution to our MACE) endpoints used to assess the safety and efficacy of cardiovascular thera ap pi pies es e . Se Se Seco co cond nd nd, , hey found that among the patient respondents to their survey, these weightings also varied as a fu unc nc cti ti tio on on o o of f f de de demo mo og gr gra aphic factors. On the basis of f f t th he ese findings, S S Sto t t lk ker er er a a and colleagues propose h h hat t t w weighted co comp mpos osit i e es es c c cou ou uld ld ld b be e e u us use ed ed to p p per r rson n nal lize e e ev evid id den n nce ce as s sses essm sm smen ent t t to to o i inf nf for or rm m m he he eal a alth h thca ca are de deli li live ve ery ry ry b bas as ased e ed o on n t th thes es se di diff f er er ren en nce ce ces. s. s.
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The cognitive and social aspects of decision-making have enjoyed intensive scrutiny in the field of behavioral economics, and business schools have long focused on preferences and choices. The present work is limited by the methods that were available, but the direction of the findings points to major areas ripe for exploration. To Stolker and colleagues' credit, they surveyed the relevant population-patients in a cardiovascular clinic. However, it is well understood that the framing of questions is of critical importance in survey-based research.
The very brief questionnaire the authors administered does not provide vignettes describing the range of disability that might be expected from nonfatal cardiovascular events;
further, it frames the question in terms of "reducing the risk of" each outcome. 1 One could assume that reducing the risk of stroke or myocardial infarction (MI) would also reduce the risk of death, and it is unclear what summative considerations went into the responses. The finding that patients rated reducing the risk of MI as equal to or more important than reducing the risk of death 1 seems to run counter to previous reports 2 ; while the clinical trialists' responses, which rated death as much more severe than nonfatal events, were consistent with prior data. 3 Other literature indicates that after more framing, patients weight nonfatal MI as less important than stroke, while they tend to assign similar importance to stroke and death. Studies using questionnaires that provided more detailed descriptions of the physical manifestations of mild or severe MI or stroke have tended to elicit much more finely grained preferences. Clearly differentiating nonfatal MI and nonfatal stroke from fatal events is a critical issue for future research.
The subgroup findings from Stolker and colleagues support a narrative that many would find pleasingly consistent with conventional wisdom. Older patients valued reducing the risk of further, it frames the question in terms of "reducing the risk of" each outcome.
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